New pill Iressa may be a viable option for patients with lung cancer who wish to forgo the negative side effects of chemotherapy.
WiredPRNews.com — As reported by the Associated press (AP), the research was published in Friday’s Lancet medical journal. The new treatment is stated to be more expensive than chemotherapy, but yields on average the same survival rates for patients with advanced lung cancer.
As noted in the AP report, more than 1.4 million people die from lung cancer every year. The drug Iressa is available to patients in the United States, but has yet to be licensed in Europe, except for with limited compassionate use. There are two other similar medications used to treat lung cancer more widely available, Tarceva and Avastin.
Iressa manufacturer, AstraZeneca PLC, paid for the study which found it to be an alternative to chemotherapy, using a sample of 1,433 advanced lung cancer cases in 24 different countries.
Details of the study result may be obtained from the recent Lancet medical journal publication.
Photo Credit: Slashme